Sphingolipids: Important players in multiple sclerosis

Cellular Physiology and Biochemistry

Volumn 34, Issue 1, 2014, Pages 111-118

  Halmer, Ramona ^a   Walter, Silke ^a   Faßbender, Klaus ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Ceramide; Multiple Sclerosis; Sphingolipids; Sphingomyelin; Sphingomyelinase; Sphingosine 1 phosphate

Indexed keywords

CERAMIDE; CYTOKINE; FINGOLIMOD; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; REACTIVE OXYGEN METABOLITE; SERINE PALMITOYLTRANSFERASE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; IMMUNOSUPPRESSIVE AGENT; LYSOPHOSPHOLIPID; PROPANEDIOL DERIVATIVE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ANTIGEN PRESENTATION; ASTROCYTE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DEMYELINATION; DENDRITIC CELL; DISEASE COURSE; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE; LYMPHOCYTE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; CLINICAL FEATURE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); ANALOGS AND DERIVATIVES; CHEMISTRY; METABOLISM; PATHOLOGY;

CERAMIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYSOPHOSPHOLIPIDS; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; SPHINGOLIPIDS; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELINS; SPHINGOSINE;

EID: 84903948813     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000362988     Document Type: Review

References (64)

1. Koch-Henriksen N, Sorensen PS: The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010;9:520-532.
2. Sospedra M, Martin R: Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747. (Pubitemid 40563183)
3. Hurwitz BJ: Analysis of current multiple sclerosis registries. Neurology 2011;76:S7-S13.
4. Simpson S Jr, Blizzard L, Otahal P, Van der Mei I, Taylor B: Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 2011;82:1132-1141.
5. Archelos JJ, Hartung HP: Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci. 2000;23:317-327. (Pubitemid 30387047)
6. Frohman EM, Racke MK, Raine CS: Medical Progress: Multiple Sclerosis-The Plaque and Its Pathogenesis. N Engl J Med 2006;354:942-955.
7. Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP: Immunopathogenesis and immunotherapy of multiple sclerosis. Nature Clin Pract Neurol 2006;2:201-211.
8. Brück W: The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 2005;252S: v3-9. (Pubitemid 41532349)
9. Bitsch A, Brueck W: Differentiation of multiple sclerosis subtypes: implications for treatment.CNS Drugs 2002;16:405-418. (Pubitemid 34638929)
10. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple Sclerosis. N Engl J Med 2000;343:938-952.
11. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C: Animal models. Ann Neurol 1994;36l:S47-S53. (Pubitemid 24220843)
12. Petry KG, Boullerne AI, Pousset F, Brochet B, Caille JM, Dousset V: Experimental allergic encephalomyelitis animal models for analyzing features of multiple sclerosis. Pathol Biol 2000;48:47-53. (Pubitemid 30136676)
13. Becher B, Bechmann I, Greter M: Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J Mol Med 2006;84:532-543. (Pubitemid 43992845)
14. Odoardi F, Sie C, Streyl K, Ulaganathan VK, Scläger, C, Lodygin D, Heckelsmiller K, Nietfeld, W, Ellwart J, Klinkert WEF, Lottaz C, Nosov M, Brinkmann V, Spang R, Lehrach H, Vingrom M, Wekerle H, Flügel Koch C, Flügel F: T cells become licensed in the lung to enter the central nervous system. Nature 2012;488:675-679.
15. Engelhardt B, Ransohoff RM: The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005; 26: 485-495. (Pubitemid 41139258)
16. Kerfoot S, Kubes P: Overlapping roles of P-selectin and a4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis, J Immunol 2002;169:1000-1006. (Pubitemid 34753459)
17. Alt C, Laschinger M, Engelhardt B: Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier suggests their involvement in G-protein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol 2002;32:2133-2144. (Pubitemid 34965876)
18. Columba-Cabezas S, Serafini B, Ambosini E, Aloisi F: Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation. Brain Pathol 2003;13:38-51. (Pubitemid 36133791)
19. Piccio L, Rossi B, Scarpini E, Laudanna C, Giagulli C, Issekutz AC, Vestweber D, Butcher EC, Constantin G: Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors. J Immunol 2002;168:1940-1949. (Pubitemid 34135797)
20. Lyck R, Engelhardt B: Going against the tide-how encephalitogenic T cells breach the blood brain barrier. J Vasc Res 2012;49:497-509.
21. Laschinger M, Vajkoczy P, Engelhardt B: Encephalitogenic T cells use LFA-1 for transendothelial migration but not during capture and initial adhesion strengthening in healthy spinal cord microvessels in vivo. Eur J Immunol 2002;32:3598-3606. (Pubitemid 36024396)
22. Battistini L, Piccio L, Rossi B, Bach S, Galgani S, Gasperini C, Ottoboni L, Ciabini D, Caramia MD, Bernardi G, Laudanna C, Scarpini E, McEver RP, Butcher EC, Borsellino G, Constantin G: CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood 2003;101:4775-4782. (Pubitemid 36857734)
23. Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T, Noelle RJ, Becher B: Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005;11:328-334. (Pubitemid 40460562)
24. Racke MK, Scott DE, Quigley L, Gray GS, Abe R, June CH, Perrin PJ: Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J Clin Invest 1995;96:2195-2203.
25. Weinberg AD, Wegmann KW, Funatake C, Whitham RH: Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 1999;162:1818-1826. (Pubitemid 29307063)
26. Agrawal S, Anderson P, Durbeej M, van Rooijen N, Ivars F, Opdenakker G Sorokin LM: Dystroleglycan is selectively cleaved ast the parenchymal basement at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med 2006;203:1007-1019.
27. Frohman EM, Filipppi M, Stuve O, Waxman SG, Corboy J, Phillips JT, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BA, Hauser S, Racke MK: Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Ann Neurol 2006;62:1345-1356. (Pubitemid 41352050)
28. Lassmann H: Multiple sclerosis: Lessons from molecular neuropathology. Exp Neurol Doi: 10.1016/j. expneurol.2013.12.003.
29. Ortiz GG, Pacheco-Moisés FP, Bitzer-Quintero OK, Ramírez-Anguiano AC, Flores-Alvarado LJ, Ramírez-Ramírez V, Macias-Islas MA, Torres-Sánchez ED: Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol Doi: 10.1155/2013/708659.
30. Cuming JN, Goodwin H: Sphingolipids and Phospholipids of Myelin in Multiple Sclerosis. Lancet 1968;21:664-665.
31. Wheeler D, Ratnam Bandaru VV, Calabresi PA, Nath A, Haughey NJ: A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 2008;131:3092-3102.
32. Haghighi S, Lekman A, Nilsson S, Blomqvist M, Andersen O: Myelin glycosphingolipid immunoreactivity and CSF levels in multiple sclerosis. Acta Neurol Scand 2012;125:64-70.
33. Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, Steinman L, Robinson WH: Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006;12:138-143. (Pubitemid 43050089)
34. Menge T, Lalive P, von Büdingen H, Cree B, Hauser S, Genain C: Antibody response against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol 2005;116:453-459. (Pubitemid 41096558)
35. Ilyas A, Chen Z, Cook S: Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J Neuroimmunol 2003;139:76-80. (Pubitemid 36700418)
36. Kim SJ, Steelman AJ, Zhang Y, Kinney HC, Li J: Aberrant upregulation of astroglial ceramide potentiates oligodendrocyte injury. Brain Pathol 2012;22:41-57.
37. Van Doorn R, van Horssen J, Verzijl D, Witte M, Ronken E, van Het Hof B, Lakeman K, Dijkstra CD, van der Valk P, Reijerkerk A, Alewijnse AE, Peters SLM, de Vries HE: Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis. Glia 2010;58:1465-1476.
38. Singh AK, Wilson MT, Hong S, Olivares-Villagómez D, Du C, Stanic AK, Joyce S, Sriram S, Koezuka Y, Van Kaer L: Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis.J Exp Med 2001;194:1801-1811. (Pubitemid 34028659)
39. Parekh VV, Wu L, Olivares-Villagómez D, Wilson KT, Van Kaer L: Activated invariant NKT cells control central nervous system autoimmunity in a mechanism that involves myeloid-derived suppressor cells. J Immunol 2013;190:1948-1960.
40. Clement AB, Gamerdinger M, Tamboli IY, Lütjohann D, Walter J, Greeve I, Gimpl G, Behl C: Adaptation of neuronal cells to chronic oxidative stress is associated with altered cholesterol and sphingolipid homeostasis and lysosomal function. Neurochem 2009;111:669-682.
41. Huwiler A, Johansen B, Skarstad Am Pfeilschifter J: Ceramide binds to the CaLB domain of cytosolic phospholipase A2 and facilitates its membrane docking and arachidonic acid release. FASEB J 2001;15:7-9.
42. Prasad VV, Nithipatikom K, Harder DR: Ceramide elevates 12-hydroxyeicosatetraenoic acid levels and upregulates 12-lipoxygenase in rat primary hippocampal cell cultures containing predominantly astrocytes. Neurochem Int 2008;53:220-229.
43. O'Keeffe J, Gately CM, Counihan T, Hennessy M, Leahy T, Moran AP, Hogan EL: T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to alpha-galactosylceramide are impaired. J Neurol Sci 2008;275:22-28.
44. Jana A, Pahan K: Oxidative stress kills human primary oligodendrocytes via neutral sphingomyelinase: Implications for multiple sclerosis. J Neuroimmune Pharmacol 2007;2:184-193.
45. Goris A, Sawcer S, Vanderbroeck K, Carton H, Billiau A, Setakis E, Compston A, Dubois B: New candidate loci for multiple sclerosis susceptibility revealed by a whole genome association screen in a Belgian population. J Neuroimmunol 2003;143:65-69. (Pubitemid 37324286)
46. Phong MC, Gutwein P, Kadel S; Hexel K, Altevogt P, Linderkamp O, Brenner B. Molecular mechanisms of L-selectin-induced co-localization in rafts and shedding. Biochem Biophys Res Commun 2003;300:563-569. (Pubitemid 38375844)
47. Futerman AH, Riezman H: The ins and outs of sphingolipid synthesis. Trend Cell Bio 2005;15:312-318. (Pubitemid 40805327)
48. Bollinger CR, Teichgräber V, Gulbins E: Ceramide-enriched membrane domains. Biochimica et Biophysica Acta 2005;1746:284-294. (Pubitemid 41815022)
49. Tischner D, Theiss J, Karabinskaya A, van den Brandt J, Reichardt SD, Karow U, Herold MJ, Lühder F, Utermöhlen O, Reichardt HM: Acid sphingomyelinase is required for protection of effector memory T cells against glucocorticoid-induced cell death. J Immunol 2011;187:4509-4516.
50. Gulbins E, Li PL: Physiological and pathophysiological aspects of ceramide. Am J Physiol Regul Integr Comp Physiol 2006;290:R11-R26.
51. Boucher LM, Wiegmann K, Futterer A, Pfeffer K, Machleidt T, Schutze S, Mak TW, Krönke M: CD28 signals through acidic sphingomyelinase. J Exp Med 2005;181:2059-2068.
52. Grassme H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K, Kolesnock R, Gulbins E: CD95 signaling via ceramide-rich membrane rafts mediate CD40 clustering. J Immunol 2002;168:298-307. (Pubitemid 34014130)
53. Rosenman SJ, Ganji AA, Tedder TF, Gallatin WM: Syn-capping of human T lymphocyte adhesion/ activation molecules and their resitrubution during interaction with endothelial cells. J Leukoc Biol 1993;53:1-10. (Pubitemid 23048042)
54. Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, DJ Heersema, van Buchem MA, De Keyser J: Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry 2008: doi: 10.1136/jnnp.2007.139345.
55. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P: Fingolimod (FTY729): discovery and development of an oral drug to treat multiple slcerosis. Nat Rev Drug Discov 2010;9:833-897.
56. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
57. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group; Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
58. Cohen JA, Chun J: Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011;69:759-777.
59. Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, Reuschel R, Beerli C, Schwarzt M, Billich A: Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 2007;323:469-475.
60. Van Doorn R, Nijland PG, Dekker N, Wite Me, Lopes-Pinheiro Ma, van Het Hof B, Kooij G, Reijerkerk A, Dijkstra C, van der Valk P, van Horssen J, de Vries HE: Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol 2012;124:397-410.
61. Groves A, Kihara Y, Cun J: Fingolimod: direct CNS effects of sphingosine-1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 2013;328:9-18.
62. Kipp M, Amor S: FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination. Mult Scler 2012;18:258-263.
63. Qin J, Berdyshev E, Goya J, Natarajan V, Dawson G: Neurons and oligodenrocytes recycle sphingosine-1-phosphate to ceramide. J Biol Chem 2010;285:14134-14143.
64. Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Lam L, Pohlmann H, Zhang-Auberson L, Dandekar A, Wallstroem E: Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial (P07.126). Neurology 2013;80 (Meeting Abstracts 1):P07.126.